Search company, investor...

Stage

Series A | Alive

Total Raised

$4.72M

Last Raised

$4.72M | 6 yrs ago

About Bionure

Bionure is a clinical-stage biotech company focused on developing therapies for neurodegenerative diseases. The company's main offerings include small molecule treatments designed to promote neuroprotection and remyelination for conditions currently lacking effective treatment options. Bionure primarily serves the biomedicine sector with a focus on neurodegenerative and neuro-inflammatory diseases. It is based in Barcelona, Spain.

Headquarters Location

Parc Científic de Barcelona Torres R+D+I, Baldiri Reixac 4-8

Barcelona, 08028,

Spain

Loading...

Loading...

Bionure Patents

Bionure has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/9/2016

10/23/2018

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Proteins

Grant

Application Date

9/9/2016

Grant Date

10/23/2018

Title

Related Topics

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Proteins

Status

Grant

Latest Bionure News

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | RemeGen, Alexion, Bionure, ENDECE, NovelMed

Jan 17, 2024

Delveinsight Business Research LLP As per DelveInsight, the Neuromyelitis Optica Spectrum Disorder Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of NMOSD and the expected launch of the pipeline therapies such as BAT4406F, RC18, HBM9161, Satralizumab (US and EU) and others in the market. DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neuromyelitis Optica Spectrum Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan). The report covers emerging Neuromyelitis Optica Spectrum Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Neuromyelitis Optica Spectrum Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. Neuromyelitis Optica Spectrum Disorder (NMOSD): An Overview Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying the current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months, or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS). Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which is present in 50% of cases. NMOSD is regarded as an autoimmune disease, though the exact cause of the autoimmunity is unknown. For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not respond to intravenous corticosteroids. For long-term suppression of the disease, a variety of immunosuppressive drugs are regarded by many clinicians as first-line therapy Symptom treatment may also involve the use of low doses of carbamazepine to control paroxysmal (sudden) tonic spasms that often occur during attacks of NMOSD and antispasticity agents to treat long term complication of spasticity that frequently develops in those with permanent motor deficits. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Key Facts According to the Orphanet, NMO has a worldwide distribution and estimated prevalence of 1-2/100,000. According to the “National Organization for Rare Disorders”, The prevalence of NMOSD is approximately 1-10 per 100,000 individuals and seems to be similar worldwide, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry. As per the National Organization for Rare Disorders, Individuals of any age may be affected, but typically NMOSD, especially cases seropositive for AQP4-IgG, occurs in late middle-aged women. Women, especially those with AQP4-IgG, are four or five times more likely to be affected than men by the recurring (relapsing) form. According to the “Siegel Rare Neuroimmune Association”, NMOSD can affect children as young as 3 years and adults as old as 90 years. The onset of NMOSD varies from childhood to adulthood, and the average age of onset is about 40. The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Neuromyelitis Optica Spectrum Disorder pipeline therapies. It also thoroughly assesses the Neuromyelitis Optica Spectrum Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics. The report gives complete details of the market trend for each marketed Neuromyelitis Optica Spectrum Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market. Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology Assessment The epidemiology section provides insights into the historical, current, and forecasted Neuromyelitis Optica Spectrum Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Neuromyelitis Optica Spectrum Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. The Report Covers the Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology, Segmented as – Total Prevalent Cases of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032) Gender-specific Prevalence of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032) Age-specific Prevalence of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032) Diagnosed Cases of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032) NMO-IgG Diagnosed Cases of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032) Neuromyelitis Optica Spectrum Disorder Drugs Uptake and Pipeline Development Activities The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Neuromyelitis Optica Spectrum Disorder market or expected to be launched during the study period. The analysis covers the Neuromyelitis Optica Spectrum Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Neuromyelitis Optica Spectrum Disorder drugs based on their sale and market share. The report also covers the Neuromyelitis Optica Spectrum Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Neuromyelitis Optica Spectrum Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Learn How the Neuromyelitis Optica Spectrum Disorder Market Will Evolve and Grow by 2032 @ Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Analysis Neuromyelitis Optica Spectrum Disorder (NMOSD) is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion. Treatment of NMO includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Preventative therapy should lower the frequency and severity of future exacerbations. Several major pharma and biotech companies are actively involved in developing therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD). Notably, RemeGen stands out among them, with NMOSD drug candidates progressing to the most advanced stage, specifically phase III of clinical trials. This highlights the dedication of these companies to advancing potential treatments for NMOSD, with RemeGen at the forefront of clinical development in addressing this neurological disorder. Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Actively Working in the Therapeutics Market Include Some of the major pharma and biotech giants such as RemeGen, Alexion Pharmaceuticals, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, NovelMed, and others are actively working in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market. Emerging and Marketed Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapies Covered in the Report Include: Telitacicept: RemeGen 4. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance 5. Neuromyelitis Optica Spectrum Disorder Disease Background and Overview 6. Neuromyelitis Optica Spectrum Disorder Patient Journey 7. Neuromyelitis Optica Spectrum Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan) 8. Neuromyelitis Optica Spectrum Disorder Treatment Algorithm, Current Treatment, and Medical Practices 9. Neuromyelitis Optica Spectrum Disorder Unmet Needs 10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment 11. Neuromyelitis Optica Spectrum Disorder Marketed Therapies 12. Neuromyelitis Optica Spectrum Disorder Emerging Drugs and Latest Therapeutic Advances 13. Neuromyelitis Optica Spectrum Disorder Seven Major Market Analysis 14. Attribute Analysis 16. Neuromyelitis Optica Spectrum Disorder Companies Active in the Market 17. Neuromyelitis Optica Spectrum Disorder Access and Reimbursement Overview 18. KOL Views on the Neuromyelitis Optica Spectrum Disorder Market 19. Neuromyelitis Optica Spectrum Disorder Market Drivers 20. Neuromyelitis Optica Spectrum Disorder Market Barriers 21. Appendix 23. Disclaimer *The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents. Request the Sample PDF to Learn More About the Key Offerings of the Report @ About DelveInsight DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Other Trending Healthcare Reports by DelveInsight “Choroideremia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Choroideremia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Choroideremia market. Media Contact

Bionure Frequently Asked Questions (FAQ)

  • Where is Bionure's headquarters?

    Bionure's headquarters is located at Parc Científic de Barcelona, Barcelona.

  • What is Bionure's latest funding round?

    Bionure's latest funding round is Series A.

  • How much did Bionure raise?

    Bionure raised a total of $4.72M.

  • Who are the investors of Bionure?

    Investors of Bionure include Alta Life Sciences.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.